Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 10/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 2/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11030583 | 0.82 | HTT (0.77) | HTTRAB9ANPC1NPSR1RXFP1 | |
| SCHEMBL19708850 | 0.82 | HTT (0.49) | HTTRAB9ANPC1NPSR1RXFP1 | |
| SCHEMBL23229125 | 0.79 | ALDH1A1 (0.64) | HTTRAB9ANPC1NPSR1RXFP1 | |
| SCHEMBL9815623 | 0.78 | HTT (0.66) | HTTRAB9ANPC1NPSR1RXFP1 | |
| SCHEMBL6002434 | 0.78 | HTT (0.60) | HTTRAB9ANPC1NPSR1RXFP1 | |
| SCHEMBL9282533 | 0.78 | HTT (0.60) | HTTRAB9ANPC1NPSR1RXFP1 | |
| SCHEMBL12729870 | 0.78 | HTT (0.55) | HTTRAB9ANPC1NPSR1RXFP1 | |
| SCHEMBL17496481 | 0.78 | HTT (0.45) | HTTRAB9ANPC1NPSR1RXFP1 | |
| SCHEMBL1474781 | 0.78 | HTT (0.55) | HTTRAB9ANPC1NPSR1RXFP1 | |
| Formaldehyde SCHEMBL28251520 | 0.77 | HTT (0.69) | HTTRAB9ANPC1NPSR1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0584222-A4 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE POULENC RORER INT (US) | 1994-07-06 | — | — | EP | claimed |
| EP-0584222-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE. | RHONE POULENC RORER INT (US) | 1994-03-02 | — | — | EP | claimed |
| CN-116634871-A | Pesticidal compounds and compositions, methods of use and methods of preparation thereof | 阿达玛马克西姆有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230046569-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-02-16 | — | — | US | disclosed |
| US-11542248-B2 | Methods and compositions for inhibiting the interaction of menin with MLL proteins | KURA ONCOLOGY, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2022-08-11 | — | — | US | disclosed |
| EP-4006030-A2 | METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS | Kura Oncology, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11324729-B2 | NSD family inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-05-10 | — | — | US | disclosed |
| WO-2007056120-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1781650-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006086381-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006021448-A1 | NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2006-03-02 | — | — | WO | disclosed |
| US-20060019959-A1 | Novel quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. TSUKUBA RESEARCH INSTITUTE (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1557418-A1 | NOVEL QUINOXALINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-0985674-B1 | ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR ALPHA-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING ALPHA-OLEFIN POLYMERS | MITSUBISHI CHEM CORP (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6255515-B1 | COORDINATION POLYMERIZATION CATALYSTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2001-07-03 | — | — | US | disclosed |
| EP-0985674-A1 | ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR $g(a)-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING $g(a)-OLEFIN POLYMERS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542248-B2 | Methods and compositions for inhibiting the interaction of menin with MLL proteins | MLLT1, MEN1, BMI1 | HTT 3417/4885RAB9A 3168/4885NPC1 3552/4885 |
| US-20230046569-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | NSD3, NSD2, NSD1 | HTT 2838/4885RAB9A 2714/4885NPC1 2107/4885 |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | HTT 3724/4885RAB9A 3429/4885NPC1 4170/4885 |
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | HTT 4456/4885RAB9A 499/4885NPC1 4257/4885 |
| US-11324729-B2 | NSD family inhibitors and methods of treatment therewith | NSD3, NSD2, NSD1 | HTT 2838/4885RAB9A 2714/4885NPC1 2107/4885 |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | HTT 4292/4885RAB9A 3585/4885NPC1 4304/4885 |
| US-20060019959-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB11 | HTT 2359/4885RAB9A 965/4885NPC1 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.